Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients
The DOI matches its Crossref record.
Abstract
Fluvoxamine and sertraline, both selective serotonin reuptake inhibitors (SSRIs), were compared in a 5‐center, 7‐week double‐blind study in outpatients with major depression diagnosed by DSM‐III‐R criteria. Ninety‐five patients were titrated from 50 to 150 mg/day offluvoxamine (n = 49) or 50 to 200 mg/day of sertraline (n = 46). The mean dose administered in Weeks 3‐1 was 123.8 mg/day for fluvoxamine, and 137.1 mg/day for sertraline. Forty‐seven percent (47%) of fluvoxamine‐treated patients and 30% of sertraline‐treated patients were titrated to the maximum permissible dose. Fluvoxamine and sertraline were similarly effective in ameliorating depression as demonstrated by a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAMD) total score of 10.61 ± 7.53 and 10.98 ± 6.08, respectively. Adverse events, mostly mild to moderate in severity, were reported for 93.5% of sertraline patients and 85.7% offluvoxamine patients. The most common events in the sertraline group were insomnia (34.8%), headache (32.6%), diarrhea (23.9%), and ejaculatory difficulty (22.2% of males), and in the fluvoxamine group, nausea (30.6%), headache (26.5%), insomnia (26.5%), and somnolence (24.5%). Significantly more patients reported sexual dysfunction in the sertraline (28%) than in the fluvoxamine (10%) group. An uncharacteristically low dropout rate due to adverse events was observed in the sertraline group (2.2%) compared with the fluvoxamine group (18.4%). The rate of withdrawal due to adverse events in the fluvoxamine group (0–2 patients/center) was comparable to that in the sertraline group (1 patient) for four of the five centers; the fifth center had 4 withdrawals in the fluvoxamine group. The differences in clinical profile of these two SSRIs provide physicians with meaningful choices in antidepressant therapy attuned to individual patient characteristics. Depression 3:163–169 (1995). © 1995 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 458
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub2 · Cited by 305
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Metadata
- Authors
- Nemeroff, C. B., Ninan, P. T., Ballenger, J., Lydiard, R. B., Feighner, J., Patterson, W. M., & Greist, J. H.
- Venue
- Depression
- Publisher
- Wiley
- Published
- 1995-01
- Volume
- 3
- Issue
- 4
- Pages
- 163-169
- ISSN
- 1062-6417 (ISSN-L)
- 1522-7162
- OpenAlex
- W2066145256
- Cited by
- 51
- References
- 0
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. https://app.cochat.ai/papers/10.1002/depr.3050030402
- The paper
- Nemeroff, C. B., Ninan, P. T., Ballenger, J., Lydiard, R. B., Feighner, J., Patterson, W. M., & Greist, J. H. (1995). Double‐blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression. https://doi.org/10.1002/depr.3050030402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.